


Listing of Claims:

1. (Currently Amended) A compound ~~Compounds~~ of ~~general~~ formula

I



in which radicals R^1 , R^2 , R^3 , R^4 and R^5 as well as R^{15} and R^{16} have the following meaning:

- R^1 is a hydrogen atom, an alkanoyl radical with 1 to 10 carbon atoms or an optionally substituted benzoyl radical with 6-10 carbon atoms or a radical CONHR^5 , whereby R^5 is a hydrogen atom, an alkyl or acyl radical with 1-10 carbon atoms in each case or an alkylaryl or aralkyl radical with 6-10 carbon atoms in each case,
- R^2 is ~~a hydrogen atom~~, a halogen atom or a CF_3 group,
- R^3 is a hydrogen atom or a group CH_2X , in which X stands for a hydrogen atom, a hydroxy group, a halogen atom, an alkyl radical with 1 or 2 carbon atoms, or X stands for a radical $(\text{CH}_2)_n\text{CH}_2\text{Y}$ with $n = 0$ or 1 , and Y stands for a halogen

atom,

whereby if

R^2 is a halogen atom, R^3 in addition can mean a group $C_nF_mH_o$, whereby $n = 1, 2,$

3, 4 or 5, $m > 1$ and $m + o = 2n + 1$,

R^4 means a hydrogen atom, an alkyl or alkanoyl radical that consists of 1-10 carbon atoms in each case or a benzoyl radical with 6-10 carbon atoms or a radical $-CONHR^5$, whereby R^5 has the above-indicated meaning, and

R^{15} and R^{16} represent hydrogen atoms or together a double bond,

~~whereby 4-[17 α -chloromethyl-17 β -hydroxy-3-oxoestra-4,9-dien-11 β -yl]benzaldehyde-1-(E)-oxime and 4-[17 α -chloromethyl-17 β -methoxy-3-oxoestra-4,9-dien-11 β -yl]benzaldehyde-1-(E)-oxime are excluded.~~

2. (Currently Amended) A compound ~~Compounds of general formula 1~~ according to claim 1, in which R^2 is a chlorine or bromine atom.

3. (Currently Amended) A compound ~~Compounds of general formula I~~ according to claim 1, in which R^3 is a hydrogen atom or a group CH_2X , in which X can be a hydrogen atom, a hydroxy group, a halogen atom, a straight-chain or branched or unsaturated alkyl radical with 1-2 ~~1-4~~ carbon atoms, a radical $(CH_2)_nCH_2Y$ with $n = 0$ or 1, and Y can be a halogen atom, and X and/or Y can be fluorine, chlorine or bromine.

4. (Currently Amended) A compound ~~Compounds~~ of general formula I, wherein characterized in that ~~in that~~ R^4 is a hydrogen atom or an alkyl radical with 1 to 4 carbon atoms.

5. (Currently Amended) A compound ~~Compounds~~ of general formula I according to claim 1, in which R^1 means a hydrogen atom, R^2 stands for a hydrogen atom, a chlorine atom or a bromine atom, and R^3 can be a hydrogen atom, a methyl group, or a CH_2-X group, whereby X stands for a fluorine, chlorine or bromine atom or a hydroxy group.

6. (Currently Amended) A compound ~~Compounds~~ of general formula I, according to claim 1, which is namely:

4-[4'-Bromo-17 β -hydroxy-3-oxoestra-4,9-dien-11 β -yl]benzaldehyde-1-(E)-oxime,

4-[4'-Bromo-17 β -hydroxy-17 α -methyl-3-oxoestra-4,9-dien-11 β -yl]benzaldehyde-1-(E)-oxime,

4-[4'-Bromo-17 β -hydroxy-17 α -trifluoromethyl-3-oxoestra-4,9-dien-11 β -yl]benzaldehyde-1-(E)-oxime,

~~4-[17 α -Bromomethyl-17 β -hydroxy-3-oxoestra-4,9-dien-11 β -yl]benzaldehyde-1-(E)-oxime,~~

~~4-[17 β -Hydroxy-3-oxoestra-4,9-dien-11 β -yl]benzaldehyde-1-(E)-oxime,~~

~~4-[17 β -Acetoxy-3-oxoestra-4,9-dien-11 β -yl]benzaldehyde-1-(E)-oxime,~~

4-[17 β -Acetoxy-4'-bromo-3-oxoestra-4,9-dien-11 β -yl]benzaldehyde-1-(E)-oxime,
4-[17 β -Acetoxy-4'-bromo-3-oxoestra-4,9-dien-11 β -yl]benzaldehyde-1-(E)-O-
acetyloxime,

~~4-[17 β -Benzoyloxy-3-oxoestra-4,9-dien-11 β -yl]benzaldehyde-1-(E)-oxime,~~
~~4-[17 β -(N-Ethylamino)carbonyloxy-3-oxoestra-4,9-dien-11 β -yl]benzaldehyde-1-~~
~~(E)-oxime,~~

~~4-[17 β -Hydroxy-3-oxoestra-4,9-dien-11 β -yl]benzaldehyde-1-(E)-[N-~~
~~(ethylamino)carbonyl]oxime,~~

~~4-[17 β -Methoxy-3-oxoestra-4,9-dien-11 β -yl]benzaldehyde-1-(E)-[N-~~
~~(ethylamino)carbonyl]oxime,~~

~~4-[17 β -Methoxy-3-oxoestra-4,9-dien-11 β -yl]benzaldehyde-1-(E)-oxime,~~
4-[4'-Bromo-17 β -methoxy-3-oxoestra-4,9-dien-11 β -yl]benzaldehyde-1-(E)-oxime,
~~4-[17 β -Hydroxy-3-oxoestra-4,9,15-trien-11 β -yl]benzaldehyde-1-(E)-oxime,~~
~~4-[17 β -Methoxy-3-oxoestra-4,9,15-trien-11 β -yl]benzaldehyde-1-(E)-oxime,~~
4-[17 β -Hydroxy-17 α -methyl-3-oxoestra-4,9-dien-11 β -yl]benzaldehyde-1-(E)-oxime,
4-[4'-Chloro-17 β -hydroxy-17 α -trifluoromethyl-3-oxoestra-4,9-dien-11 β -
yl]benzaldehyde-1-(E)-oxime,

4-[4'-Chloro-17 β -hydroxy-3-oxoestra-4,9-dien-11 β -yl]benzaldehyde-1-(E)-oxime,
~~4-[17 α -Fluoromethyl-17 β -hydroxy-3-oxoestra-4,9-dien-11 β -yl]benzaldehyde-1-~~
~~(E)-oxime,~~

4-[4'-Bromo-17 α -fluoromethyl-17 β -hydroxy-3-oxoestra-4,9-dien-11 β -yl]benzaldehyde-

1-(E)-oxime,

4-[4'-Bromo-17 α -chloromethyl-17 β -hydroxy-3-oxoestra-4,9-dien-11 β -yl]benzaldehyde-

1-(E)-oxime,

4-[4'-Bromo-17 α -bromomethyl-17 β -hydroxy-3-oxoestra-4,9-dien-11 β -yl]benzaldehyde-

1-(E)-oxime,

4-[4'-Chloro-17 β -methoxy-3-oxoestra-4,9-dien-11 β -yl]benzaldehyde-1-(E)-oxime,

4-[4'-Chloro-17 α -chloromethyl-17 β -hydroxy-3-oxoestra-4,9-dien-11 β -yl]benzaldehyde-

1-(E)-oxime,

~~4-[17 β -Ethoxy-3-oxoestra-4,9-dien-11 β -yl]benzaldehyde-1-(E)-oxime,~~

~~4-[17 β -Isopropoxy-3-oxoestra-4,9-dien-11 β -yl]benzaldehyde-1-(E)-oxime,~~

~~4-[17 β -Benzyloxy-3-oxoestra-4,9-dien-11 β -yl]benzaldehyde-1-(E)-oxime,~~

4-[17 β -Methoxy-4'-trifluoromethyl-3-oxoestra-4,9-dien-11 β -yl]benzaldehyde-1-

(E)-oxime, or

4-[4'-Chloro-17 β -hydroxy-17 α -methyl-3-oxoestra-4,9-dien-11 β -yl]benzaldehyde-1(E)-

oxime,

~~4-[17 β -Hydroxy-17 α -methyl-3-oxoestra-4,9-dien-11 β -yl]benzaldehyde-1-(E)-[O-~~

~~(ethylamino)carbonyl]oxime;~~

~~4-[17 β -Hydroxy-17 α -hydroxymethyl-3-oxoestra-4,9-dien-11 β -yl]benzaldehyde-1-(E)-[O-~~

~~(ethylamino)-carbonyl]oxime.~~

7. (Currently Amended)

A pharmaceutical composition comprising

~~Pharmaceutical preparations that contain at least one compound of general formula I according to claim 1 and as well as a pharmaceutically compatible vehicle.~~

8. (Currently Amended) A method ~~Use of the compounds of general formula I according to one of claims 1 to 6 for the production of pharmaceutical agents for female birth control, comprising administering to a female a compound of claim 1.~~
9. (Currently Amended) A method ~~Use of the compounds of general formula I according to one of claims 1 to 6 for the production of pharmaceutical agents for treating dysfunctional bleeding, comprising administering to a host in need thereof a compound of claim 1.~~
10. (Currently Amended) A method ~~Use of the compounds of general formula I according to one of claims 1 to 6 for the production of pharmaceutical agents for treating a dysmenorrhea, comprising administering to a host in need thereof a compound of claim 1.~~
11. (Currently Amended) A method ~~Use of the compounds of general formula I according to one of claims 1 to 6 for the production of pharmaceutical agents for inducing an amenorrhea, comprising administering to a host in need thereof a~~

compound of claim 1.

12. (Currently Amended) A method ~~Use of the compounds of general formula~~
~~I according to one of claims 1 to 6 for the production of pharmaceutical agents for~~
~~treating hormonal disorders in postmenopausal women, comprising administering~~
~~to a host in need thereof a compound of claim 1.~~

13. (Currently Amended) A process ~~Use of the compounds of general formula~~
~~I according to one of claims 1 to 6 for the production of pharmaceutical agents for~~
~~treating endometriosis or as well as uterus myomatoses, whereby 4-[17 α -~~
~~chloromethyl-17 β -hydroxy-3-oxoestra-4,9-dien-11 β -yl]benzaldehyde-1-(E)-~~
~~oxime and 4-[17 α -chloromethyl-17 β -methoxy-3-oxoestra-4,9-dien-11 β -~~
~~yl]benzaldehyde-1-(E)-oxime are excluded comprising administering to a host in~~
~~need thereof a compound of claim 1.~~

14. (Currently Amended) A method ~~Use according to claim one of claims 8 to~~
~~10, wherein the compound is administered~~ in combination with at least one low-
dose natural or synthetic estrogen or prodrug ~~prodrugs~~ thereof.

15. (Currently Amended) A method ~~Use according to claim 14 11, comprising~~
~~using an wherein the estrogen as its~~ is used as 3-sulfamate.

16. (Currently Amended) A method Use according to claim 15 ~~12~~, wherein
the estrogen-3-sulfamate is 17 β -hydroxy-estra-1,3,5(10)-trien-3yl-sulfamate.

17. (New) A method for the production of a pharmacological agent,
comprising bringing together a compound of claim 1 and a pharmacologically
acceptable carrier.